Frontlight ResearchEarly access
CompletedNo phase
MiDura-Study (Neuro-Patch in Duraplasty)
Key facts
- Who runs it
- Aesculap AG
- Where
- France and Germany4 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 328 people enrolled
- Started
- 6 Feb 2020
- Ended
- 26 Nov 2025
- Type of study
- Observational
- Record updated
- 5 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Written informed consent
- Age > 18 years
- Duraplasty using Neuro-Patch® according to the Instructions for Use
Who cannot take part
- Use in infected regions
- Known hypersensitivity to implant materials
- Use in open cerebrocranial traumata
- Use in open spina bifida
- Pregnancy
- Representation by a legal guardian or under involuntary commitment
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to collect systematically and proactively data regarding the performance of Neuro-Patch, like complications and handling, under daily clinical practice when used as intended by the manufacturer
The group in the trial
- Neuro-Patch
Patients receiving Neuro-Patch® for duraplasty
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Multicenter, International, Prospective, Observational, Study Using Neuro-Patch® in Duraplasty in Neurosurgery (MiDura)
- Record updated
- 5 November 2026